Ora’s ocular models have been supporting companies for decades, helping them move their product through the clinic quickly. This translates well when exploring anti-inflammatory candidates. Let us show you how!
The Ora team has translated the reliable, validated Ora-CAC® model into an approach to help you with your indication expansion and anti-inflammatory product development efforts. We use the eye as a surrogate for inflammation in a proprietary ocular allergic model to evaluate anti-inflammatory products. Using in-vivo confocal microscopy of the ocular surface, Ora has the ability to show – in real time – the impact a product is having on the various stages of ocular inflammation.
In this case, you go straight into the clinical trials process.
This is beneficial because you can get to a decision quickly on if your product has efficacy in inflammation. Within 12 – 24 months, depending on formulation and animal studies, you can get into the clinic.
If you find efficacy in the POC, then we can work together on a preclinical and clinical approach to change the route of administration to a new administration route.
If you change the route of administration at the beginning of the process, you must first do a preclinical toxicology program before you go into the clinical trials process.